LeMaitre Vascular, Inc. (LMAT)
NASDAQ: LMAT · Real-Time Price · USD
84.21
-1.49 (-1.74%)
Dec 5, 2025, 3:40 PM EST - Market open
LeMaitre Vascular Revenue
LeMaitre Vascular had revenue of $61.05M in the quarter ending September 30, 2025, with 11.36% growth. This brings the company's revenue in the last twelve months to $240.87M, up 13.07% year-over-year. In the year 2024, LeMaitre Vascular had annual revenue of $219.86M with 13.63% growth.
Revenue (ttm)
$240.87M
Revenue Growth
+13.07%
P/S Ratio
8.04
Revenue / Employee
$362,750
Employees
664
Market Cap
1.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 219.86M | 26.38M | 13.63% |
| Dec 31, 2023 | 193.48M | 31.83M | 19.69% |
| Dec 31, 2022 | 161.65M | 7.23M | 4.68% |
| Dec 31, 2021 | 154.42M | 25.06M | 19.37% |
| Dec 31, 2020 | 129.37M | 12.13M | 10.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LMAT News
- 22 days ago - LeMaitre to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - LeMaitre Vascular, Inc. (LMAT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - LeMaitre Q3 2025 Financial Results - GlobeNewsWire
- 2 months ago - LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025 - GlobeNewsWire
- 2 months ago - LeMaitre Vascular: Investment Debate Remains In Place - Seeking Alpha
- 3 months ago - LeMaitre to Participate at Upcoming Investor Conferences in September - GlobeNewsWire
- 4 months ago - LeMaitre (LMAT) Q2 Revenue Jumps 15% - The Motley Fool
- 4 months ago - LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript - Seeking Alpha